Cervical cancer burden and prevention strategies: Asia oceania perspective

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 9, 2012, Pages 1414-1422

  Garland, Suzanne M ^a,b,c,d   Bhatla, Neerja ^e   Ngan, Hextan Y S ^f  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; CANCER VACCINE; LUGOL; VIRUS DNA; WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CANCER SCREENING; CONDYLOMA ACUMINATUM; CYTOPATHOLOGY; DRUG COST; DRUG EFFICACY; GENOTYPE; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; LOWEST INCOME GROUP; PAPANICOLAOU TEST; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK REDUCTION; SEXUAL HEALTH; STANDARDIZATION; UTERINE CERVIX CANCER; WART VIRUS;

ASIA; COST OF ILLNESS; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HEALTH EDUCATION; HUMANS; INCIDENCE; OCEANIA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84866159233     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0164     Document Type: Review

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010 [cited 2012 Mar 12]. Available from: http://globocan.iarc.fr.
2. Konno R, Shin H-R, Kim Y-T, Song YS, Sasagawa T, Inoue M. Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine 2008;26:M30-42.
3. Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. Vaccine 2008;26 Suppl 12:M60-70.
4. Garland SM, Brotherton JML, Skinner SR, Pitts M, Saville M, Mola G, et al. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention. Vaccine 2008;26 (Supl 12):M80-8.
5. Domingo EJ, Noviani R, Noor MR, Ngelangel CA, Limpaphayom KK, Thuan TV, et al. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine 2008;26 Suppl 12:M71-9.
6. Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO, Ashrafunnessa KS, et al.Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 2008;26 Suppl 12:M43-52.
7. Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, et al. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine 2008;26 Suppl 12:M89-98.
8. Garland S, Park SN, Ngan HY, Frazer I, Tay EH, Chen CJ, et al. The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGIN conference. Vaccine 2008;26:5435-40.
9. Shi JF, Qiao YL, Smith JS, Dondog B, Bao YP, Dai M, et al. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine 2008;26 Suppl 12:M53-9.
10. AIHW 2009. Cervical screening in Australia 2006-2007. Cancer series no. 47. Cat. no. CAN 43. Canberra: AIHW. Viewed 14 June 2012 http://www.aihw.gov.au/ publication-detail/?id=6442468228.
11. AIHW 2011. Cervical screening in Australia 2008-2009. Cancer series no. 61. Cat. no. CAN 57. Canberra: AIHW http://www.aihw.gov.au/publication-detail/? id=10737420251.
12. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36.
13. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
14. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary Report 2010. [accessed on 23 April 2012]. Available at www.who.int/hpvcentre
15. Liaw KL, Hsing AW, Schiffman MH, You SL, Zhang T, Burk R, et al. Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women. Int J Cancer 1997;73:775-76.
16. Chen CA, Liu CY, Chou HH, Chou CY, Ho CM, Twu NF, et al. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan Cooperative Oncologic Group Study. Int J Gynecol Cancer 2006;16:1801-08.
17. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 2002;94:1249-53.
18. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006;102:54-60.
19. Lai HC, Peng MY, Nieh S, Yu CP, Chang CC, Lin YW, et al. Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis. Int J Gynecol Cancer 2006;16:730-35.
20. Bilous J, Eggers R, Gasse F, Jarrett S, Lydon P, Magan A, et al. A new global immunisation vision and strategy. Lancet Infect Dis 2006;6:1464-6.
21. Gertig DM, Brotherton JML, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sexual Health 2011;8:171-8.
22. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2010;11:39-44.
23. Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
24. Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program JID In Press.
25. GAVI takes first steps to introduce vaccines against cervical cancer and rubella. [cited 2011 Dec 2]. Geneva, Switzerland; 2011. Available at http://www.gavialliance.org.
26. Ministry of Health, Labour and Welfare. Available from: http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/index.html. accessed 23 April 2012.
27. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bulletin of WHO 2011;89:821-30B.
28. AOGIN (Asia-Oceania Research Organisation in Genital Infection & Neoplasia). Available from: www.aogin.com
29. Pitts M, Smith A, Croy S. "Singaporean women's knowledge of human papillomavirus HPV) and attitudes toward HPV vaccination," Women Health. 2009;49:334-51.
30. Pitts M, Smith A, Croy S. "Singaporean men's knowledge of cervical cancer and human papillomavirus (HPV) and their attitudes towards HPV Vaccination,". Vaccine 2009;27:2989-93.
31. Bao YP, Putra AD, Park JS, Kim YT, Ruey S, Limson G, et al. Human papillomavirus type-distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008;18:71-9.
32. Bhatla N, Lal N, Bao YP, Ng T, Qiao YL. A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine 2008;26:2811-7.
33. Ngan HY, Garland SM, Bhatla N, Pagliusi SR, Chan KK, Cheung AN, et al. Asia Oceania guidelines for the implementation of programs for cervical cancer prevention and control. J Cancer Epidemiol 2011;2011:794861. Epub 2011 Apr 13.
34. Tabrizi SN, Law I, Buadromo E, Stevens M, Fong J, Samuela J, et al. HPV genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Fiji. Sex Health 2011;8:338-342.
35. Samarawickrema NA, Tabrizi SN, Hewavisenthi J, Leong T, Garland SM. Distribution of human papillomavirus genotypes in archival cervical tissue from women with cervical cancer in urban Sri Lanka. Int J Gynaecol Obstet 2011;115:180-2.
36. Zerhouni EA. Translational and Clinical Science-Time for a New Vision. N Engl J Med 2005 353 1621-3.
37. Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer 2010;20:385-92.
38. Kim YT. Current Status of Cervical cancer and HPV Infection in Korea. J Gynecol Oncol 2009;20:1-7.